Hostname: page-component-cd9895bd7-gvvz8 Total loading time: 0 Render date: 2024-12-26T16:43:10.507Z Has data issue: false hasContentIssue false

Is Cholesterol a Culprit in Alzheimer's Disease?

Published online by Cambridge University Press:  10 January 2005

D. Larry Sparks
Affiliation:
Laboratory for Neurodegenerative Disease Research, Sun Health Research Institute, Sun City, Arizona, US Division of Medical Examiner Services, Kentucky Justice Cabinet, Frankfort, Kentucky, US
Marwan N. Sabbagh
Affiliation:
Cleo Roberts Center for Clinical Research, Sun Health Research Institute, Sun City, Arizona, US
John C. S. Breitner
Affiliation:
Department of Mental Hygiene, School of Hygiene and Public Health, The Johns Hopkins University, Baltimore, Maryland, US
John C. Hunsaker III
Affiliation:
Division of Medical Examiner Services, Kentucky Justice Cabinet, Frankfort, Kentucky, US Department of Mental Hygiene, School of Hygiene and Public Health, The Johns Hopkins University, Baltimore, Maryland, US
Get access

Abstract

A pivotal role for cholesterol influence on production of the putative AD toxin, amyloid β (Aβ), has been amply demonstrated. More importantly, this relationship has consistently been identified in both in vivo and in vitro studies. Lowering cholesterol levels has been shown to cause a beneficial effect on Aβ levels in animal models, and epidemiological data indicate a beneficial effect on the risk of AD with prior statin use. Blinded, placebo-controlled clinical investigations assessing the benefit of statins on cognitive indices in mild to moderate AD are ongoing and one will be reported on soon. A prospective study assessing the effect of statin use on the risk of AD is under way as an observational component of a placebo-controlled primary prevention trial testing anti-inflammatory agents. Nevertheless, the foregoing suggests that routine monitoring and intervention for elevated cholesterol levels among the elderly could promote more than a healthy heart.

Type
PRIMARY PREVENTION (BRAIN AT RISK OF CVD)
Copyright
© 2003 International Psychogeriatric Association

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)